Effects of sex hormones on bronchial reactivity during the menstrual cycle by Matteis, Maria et al.
 
Effects of sex hormones on bronchial reactivity during the
menstrual cycle
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Matteis, M., F. Polverino, G. Spaziano, F. Roviezzo, C.
Santoriello, N. Sullo, M. R. Bucci, et al. 2014. “Effects of sex
hormones on bronchial reactivity during the menstrual cycle.”
BMC Pulmonary Medicine 14 (1): 108. doi:10.1186/1471-2466-
14-108. http://dx.doi.org/10.1186/1471-2466-14-108.
Published Version doi:10.1186/1471-2466-14-108
Accessed February 16, 2015 4:19:29 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:12717548
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAARESEARCH ARTICLE Open Access
Effects of sex hormones on bronchial reactivity
during the menstrual cycle
Maria Matteis
1†, Francesca Polverino
2,4,5†, Giuseppe Spaziano
1, Fiorentina Roviezzo
3, Carlo Santoriello
4, Nikol Sullo
1,
Maria Rosaria Bucci
3, Francesco Rossi
1, Mario Polverino
4, Caroline A Owen
2,4 and Bruno D’Agostino
1*
Abstract
Background: Many asthmatic women complain of symptom exacerbations in particular periods, i.e. during
pregnancy and menstrual cycles (perimenstrual asthma: PMA)". The goal of this study was to study the effect of the
luteal and follicular phases of the menstrual cycle on bronchial reactivity (BR) in a group of asthmatic women.
Methods: For this purpose, 36 pre-menopausal women were enrolled and underwent testing for resting pulmonary
function, measurement of the diffusing capacity of the lung for carbon monoxide (DLCO), and airway responsiveness
to methacholine in the follicular and luteal phases of their menstrual cycles. We also measured plasma hormone levels
and levels of cyclic adenosine monophosphate (cAMP; a mediator of bronchial smooth muscle contraction) and
testosterone in induced sputum samples.
Results: Our study showed that about 30% of the asthmatic women had decreased PC20FEV1.0 in the follicular phase of
menstrual cycle with a significant correlation between PC20FEV1.0 and serum testosterone levels. Moreover, marked
increases in sputum testosterone levels (mean=2.6-fold increase) together with significant increases in sputum cAMP
concentrations (mean=3.6-fold increases) were observed during the luteal phase of asthmatic patients, suggesting that
testosterone contributes to the pathophysiology of PMA. We excluded the possibility that testosterone directly inhibits
phosphodiesterase (PDE) activity as incubating PDE with testosterone in vitro did not reduce PDE catalytic activity.
Conclusions: In conclusion, our data show that PC20FEV1.0 was decreased in the follicular phase of the menstrual cycle
in about 30% of women and was associated with lower cAMP levels in sputum samples, which may contribute to
bronchoconstriction. Our results also suggest a link between PMA and testosterone levels. However, whether these
findings are of clinical significance in terms of the management of asthma or asthma worsening during the menstrual
cycle needs further investigation.
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Background
Asthma is a chronic inflammatory disorder of the airways
[1] in which many cells and cellular elements play a role
[2,3]. The incidence, severity, and prognosis of asthma can
be affected by several factors, including the patient’sa g e
and sex. Epidemiological studies of both incidence and
prevalence have reported a male predominance of asthma
before puberty and a female predominance after puberty.
Sex differences exist in the risk, incidence, and patho-
genesis of various lung diseases in humans [4]. Females
typically are more susceptible and/or develop more severe
asthma, chronic obstructive pulmonary disease, lung can-
cer, and other lung conditions. Accumulating epidemio-
logical and experimental data suggest that sex hormones
may be important physiological modulators in the lung,
and the role of estrogens in asthma has received consider-
able attention in this regard.
It has been known for a long time that some female
asthmatic patients experience an aggravation of asthma
symptoms during the premenstrual or menstrual phases
of their cycle. In particular, it has been hypothesized
that hormonal fluctuations during the menstrual cycle
play a significant role in the pathophysiology of asthma,
resulting in periodic worsening of disease severity in
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menstrual, or perimenstrual asthma (PMA) have been used
to describe this phenomenon. Various approaches have
been adopted to investigate the hormonal hypothesis. How-
ever, the roles of gender and sex hormones in asthmatic
women are complex and not completely understood. A
more complete understanding of the activities of hormones
in regulating asthma exacerbations could introduce new
strategies for symptom management and decrease the dis-
ease burden associated with this phenomenon.
Therefore, the goal of this project was to study the effect
of the menstrual cycle; specifically, the luteal and follicular
phases and plasma sex hormone levels, on bronchial re-
activity (BR) in a group of asthmatic women. In particular,
sex hormone levels and mediators of bronchial smooth
muscle contraction were evaluated.
Methods
Human study
Study population
To study the relationship between bronchial reactivity and
sexual hormones in menstrual cycle, 56 asthmatic pre-
menopausal women were recruited from the outpatient
clinics of the Respiratory Department of Cava de’ Tirreni
Hospital. We recruited women suffering from allergic
asthma and documented bronchial hyperreactivity. We ex-
cluded women with a history of lung diseases other than
asthma, coronary artery disease, congestive heart failure,
or cor pulmonale. After accounting for refusals to partici-
pate (n=11), inadequate information on asthma status
(n =3), and non-participation for other reasons (n=4), 38
women (70.4%) were enrolled in the study. After enroll-
ment, 2 women were excluded because of data missing. A
total of 36 females, aged between 23 and 43 years-old
(mean: 32.6±SD 4.3 yrs-old) completed the study. Among
them, 5 were mild smokers with a smoking history of 8.2 ±
2.9 pack/years. No subjects were using oral or intrauterine
contraceptives. Obesity, defined as a BMI ≥30 kg/m
2,w a s
present (<35 kg/m
2) in 5 females. At the time of the study,
none of the patients had experienced recent acute exacer-
bations, and all of them were clinically stable.
Twenty-six (72%) of the subjects had intermittent
asthma, due to pollen aeroallergens: six patients (17%)
were sensitized to one allergen, twelve patients (33%) were
sensitized to two allergens, and eight patients (22%) to
three allergens. The remaining ten (28%) women had per-
sistent asthma, mainly due to perennial aeroallergens: five
of them (14%) were sensitized to one allergen, and five
(14%) were sensitized to two allergens. The mean values of
total serum IgE were 449.7 (±336.9) kU/L in the first
group (patients with intermittent disease) and 934.2
(±765.8) kU/L in the second group (patients with persist-
ent disease). There was no significant correlation between
severity of asthma and RASTclasses.
The local Ethics Committee “ASL Salerno” approved the
study (n° 357/CdE of September 12, 2012) and all respon-
dents provided informed consent before participation.
At the time of enrollment, women were interviewed and
completed a standardized questionnaire that included
questions about demographic factors, pregnancy history,
health care utilization, smoking history, years of education
completed, marital status, asthma history, activity limita-
tions due to asthma, household exposures, asthma-related
emergency visits, use of drugs to treat asthma, and other
chronic conditions.
Measurement of IgE mediated hypersensitivity
The patients underwent intradermal skin testing for IgE-
mediated hypersensitivity. Allergy skin-prick tests were car-
ried out using 14 common aeroallergen extracts (Lofarma,
Italy): Dermatophagoides (D.) farinae, D. pteronyssinus, cat,
dog, ragweed mix, grass mix (Timothy, June, Orchard), ash,
beech, birch, hickory, oak, poplar, and the molds Aspergillus
and Alternaria tenuis. Histamine (1 mg/mL) and saline
(0.9%) solutions were used as positive and negative controls,
respectively. Diagnosis of asthma was made on the basis of
a history of asthma and the presence of a positive radioaller-
gosorbent test (RAST) for IgE antibodies (RAST-CAP-
FEIA, Pharmacia, Uppsala, Sweden). Only women in whom
there was an agreement between the results of the skin prick
tests and the results of RAST were selected for the study.
Pulmonary function test
Patients were asked to refrain from using short-acting ß2-
agonists or caffeine-containing beverages for 12 h prior to
testing. All enrolled subjects underwent assessment of pul-
monary function at rest and measurement of DLCO and
airway responsiveness to methacholine as outlined below.
These tests were done twice on every subject both during
the follicular and luteal phases of the menstrual cycle.
Spirometry
Measurements were performed according to American
Thoracic Society criteria [12]. Spirometric maneuvers were
conducted in triplicate and the highest FEV1.0 and FVC
values were used in subsequent analyses. Predicted normal
values of FEV1.0 and FVC were derived from standard
equations. SVC was obtained by a slow inspiration from
maximal end expiratory lung volume, before flow-volume
loop measurement.
Lung diffusion
Diffusion capacity for carbon monoxide (DLCO; transfer
factor) was obtained by the single-breath method and ad-
justed for hemoglobin and alveolar volume to yield the
diffusion coefficient (KCO). For this purpose, subjects in-
spired gas atmospheric air mixtures containing 0.3% CH4
and 0.3% CO.
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Cholinergic responsiveness was evaluated by challenging
subject with increasing concentrations of inhaled methaco-
line approved following consensus recommendations. The
magnitude of the effect was expressed as percentage of
change from the control value (% ΔFEV1). Airway reactivity
was measured by inhaling increasing concentrations of
methacholine from a DeVilbis nebulizer with a breath-
synchronized trigger. The initial concentration of 1 mg/ml
was progressively doubled until the FEV1.0 fell by ≥20%
from its original value, and the provocative concentration
(PC20meth) required to achieve this end point was deter-
mined by linear interpolation. The concentrations of metha-
choline were doubled also above the usual maximum
concentration of 25 mg/ml in order to obtain a fall of
FEV1.0 greater than 20% from the basal value in all subjects.
Concentrations of methacholine greater than 25 mg/ml
were required in 16 challenges (6 in the follicular phase and
10 in the luteal phase): 2 women needed a concentration
greater than the usual maximum only in the follicular phase,
6 women only in the luteal phase, and 4 women in both
phases. Bronchodilatation with standard aerosols of albute-
rol was done in order to reverse cholinergic responsiveness.
Hormonal assessments
A venous blood sample was drawn from each participant
between 8 AM and 10 AM and serum was obtained by
centrifugation. Serum aliquots were then stored at −80°C
until analysis.
Prolactin, follicule-stimulating hormone (FSH), lute-
inizing hormone (LH), testosterone (T), progesterone
(PRG) and 17β-estradiol (E2) were measured in all sam-
ples using an electrochemiluminescence immunoassay
(ElecsysSystem, Roche Diagnostics GmbH, Mannheim,
Germany) according to the manufacturer's instructions.
Collection and analysis of induced sputum
Induced sputum was collected pre- and post-shift by inhal-
ation of isotonic (0.9%) saline aerosol, in both the follicular
and the luteal phases of the menstrual cycle, placed at 4°C
and immediately sent to the laboratory. After centrifuga-
tion, aliquots of the supernatant fluids were stored at −80°C
until further analysis. Cyclic AMP (cAMP) and testoster-
one levels were measured using Enzyme Immunoassays
(Cayman-EIA kit, Michigan, USA). Moreover, PDE activity
was evaluated using a PDE assay kit (BPS Bioscience, San
Diego, CA). The measurements (PFTs, PC20, and blood
collection) were performed on day 1±3 days of menstru-
ation and 14±3 days after the start of menstruation.
In vitro study
PDE activity assay
The ability of testosterone to modulate PDE activity
was evaluated by a colorimetric cyclic nucleotide
phosphodiesterase assay, according to manufacturer in-
structions. This assay measures PDE mediated cleavage of
cyclic adenosine monophosphate (cAMP) yielding 5’ adeno-
sine monophosphate (5’AMP), which is further cleaved into
its nucleosides and phosphate components. The phosphate
generated was quantified by a colorimetric reaction with
Biomol green. A non-specific PDE inhibitor, 3-isobutyl-1-
methylxanthine (IBMX), was included as positive control
for inhibitor screening. Physiologically-relevant concentra-
tions of testosterone detected in plasma samples in normal
human female subjects (0.3 and 1 nM) were tested and
compared to IBMX (40 μM).
Statistical analysis
Statistical analyses for the human study
Group data are expressed as mean (±SD). As our data are
generated from small patient populations and these data
that are not normally distributed, we used the Mann–
Whitney U-test for comparison between non-parametric
results. The Spearman's rank correlation coefficient test
was used to examine the association between functional
data and hormone levels. These analyses were performed
using the statistical package SPSS 17.0.
Statistical analyses for in-vitro evaluations
We performed analyses with two-way ANOVA within
groups, followed by the Bonferroni test to correct for mul-
tiple comparisons. Data are presented as means±SEM.
Statistical analyses were performed using GraphPad
Prism version 4.7 (GraphPad, San Diego, CA).
Statistical significance was defined as P<0.05.
Results
The human study
Among the 36 study subjects studied, 23 had at least one
pregnancy with a total of 31 births (with 14 male and 17 fe-
male offspring). In 1 out of 14 male births, mothers re-
ported an overall deterioration in symptoms, and in 2 out
of 14 male births, mothers reported an improvement in
symptoms. However, in 2 out of 17 female births, mothers
reported an overall deterioration in symptoms but no
mothers of female offspring reported improvement in
symptoms. Twelve out of 36 women complained occasion-
ally of perimenstrual asthma, but no patient complained of
perimenstrual asthma during the study.
PFTs
Pulmonary function tests showed the absence of restrictive
or obstructive defects, as detected by normal total lung
capacity with normal FEV1.0/FVC ratio and normal DLCO
values in both the follicular and the luteal phases of the
menstrual cycle in all study subjects. The mean values for
PC20FEV1.0 were not significantly different when mea-
sured either in the follicular and the luteal phases (Table 1).
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licular and luteinic phases showed that 10 out of 36
(27.8%) of the women had lower PC20FEV1.0 values during
the follicular phase (Figure 1).
Plasma hormones
Table 2 shows mean values (±1 S.D.) of plasma hormones
during the follicular and luteal phases, and Figures 2, 3
and 4 show the relationships between any hormone (inde-
pendent variable) and PC20FEV1.0 (dependent variable).
Statistically significant differences were obtained only
when correlating PC20FEV1.0 and plasma testosterone
levels suggesting that testosterone modulates BR. A step-
wise regression analysis, in which all clinical, functional,
and hormonal data from both phases of the menstrual
cycle were included, identified plasma testosterone levels
as the only independent variable (Figure 2A).
Cyclic AMP (cAMP) levels, testosterone levels and PDE
activity in induced sputum
Cyclic AMP is a key intracellular mediator that contrib-
utes to bronchoconstriction in asthmatic airways. Accord-
ingly, we evaluated whether cAMP is present in asthmatic
sputum samples and correlates with different phases of
the menstrual cycle. As shown in Figure 5, sputum cAMP
levels were significantly higher in the luteal phase when
compared with the follicular phase of the menstrual cycle.
Interestingly, measurement of testosterone levels in the
same samples revealed a similar profile, with significantly
higher sputum levels of testosterone in the luteal phase
compared with the follicular phase of menstrual cycle
(Figure 6). Cyclic AMP levels are regulated by phospho-
diesterases, which hydrolyze and thereby, reduce cAMP
levels in cells. Thus, we measured PDE activity in spu-
tum samples from the our asthmatic patients. Sputum
PDE activity showed a different trend when compared
with to those of cAMP and testosterone, as they were
lower in the luteal phase when compared with sputum
PDE activity levels measured in the follicular phase of
menstrual cycle (Figure 7).
In vitro study
Testosterone does not reduce PDE activity in vitro
Next, we assessed whether testosterone directly reduces
PDE activity to thereby increase cAMP levels in airway
samples from patients with asthma. To assess this possibil-
ity, we incubated cell-free, purified PDE with or without
two different concentrations of testosterone in vitro, and
measured residual PDE activity. As shown in Figure 8, tes-
tosterone had no direct effect on PDE activity at either
concentration tested. Thus, it is unlikely that testosterone
modulates cAMP levels in asthmatic airways by directly
interfering with PDE activity.
Discussion
Perimenstrual worsening of asthma with an increase in
symptoms and significant decline in peak flow (20%) has
been reported in 30-40% of women [13]. Our study, car-
ried out on 36 asthmatic women, has documented that
10 out of 36 (27.8%) of them showed a trend towards a
lower PC20FEV1.0 in the follicular phase when compared
with their response in the luteal phase (or vice versa).
However, this result was not statistically significant due
to the high degree of variability between subjects, and
was not clinically evident in terms of asthma-related
symptoms. In this study, we have also demonstrated that
in the luteal phase of menstrual cycle the mean level of
testosterone in both sera and induced sputum samples is
increased when compared with mean levels measured in
the follicular phase. Higher testosterone levels in sputum
samples were, in turn, associated with higher cAMP
levels and lower PDE activity in sputum samples during
Table 1 Mean values of pulmonary function tests
performed on asthmatic women in the follicular and
luteal phases of menstrual cycle
FVC FEV1.0 PEF FEF DLCO PC20.0
% pred. % pred. % pred. % pred. % pred. mg/ml
Follicular 103±13 94±15 78±17 72± 33 82±30 21±46
Luteal 97± 28 91±18 76±21 65± 26 81±22 35±56
P> 0,05.
Figure 1 Correlation between the provocative concentration of
methacoline (PC20meth) required to obtain a reduction in
FEV1.0 ≥20% from the baseline value. On the x-axis: PC20meth
values measured in the follicular phase; on the y-axis: PC20meth
values measured in the luteal phase. About 30% of the women had
lower PC20FEV1.0 values during the follicular phase (and vice versa).
A logarithmic scale is used on both axes.
Table 2 Mean values (±1 S.D) of plasma hormones during
the follicular and luteal phases
FSH PRL TST LH ESTR PRG
mUI/mL ng/mL ng/ml mUI/mL pg/mL ng/mL
Follicular 18± 14 8± 3 0,33±0,09 21±12 47±20 1,46±1,57
Luteal 12+ 8 10+4 0,36+0,14 16+ 18 63+40 4,15+4,40
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the generation of cAMP by reducing PDE activity.
A few studies have focused on bronchial hyperrespon-
siveness to various constrictor agents during the menstrual
cycle in asthmatic women [8,9,13-18], but no cyclical varia-
tions were found in the subjects’ responses to methacholine
or histamine challenges [8,9,13,14]. However, two studies
by Tan et al. [15,16] showed an increase in PC20 in re-
sponse to adenosine monophosphate challenges in the lu-
teal phase when compared with responses in the follicular
phase. This could indicate an effect of female sex hor-
mones on airway inflammation during the menstrual
cycle, as changes in AMP closely reflect changes in eosino-
philic airway inflammation [17-19].
Women of reproductive age experience cyclic varia-
tions in serum concentrations of sex hormones [20].
During the 4 days after menstruation, FSH, LH, 17-β-
estradiol, progesterone, and testosterone levels are
low. During the follicular phase of the menstrual cycle,
progesterone and testosterone serum levels remain
low, while levels of FSH and LH peak. Finally, during
the luteal phase, FSH and LH levels are low, whereas
17-β-estradiol, progesterone, and testosterone are
moderately high [20].
Clinical observations indicate that the hormonal fluc-
tuations described above might be responsible for the
cyclic changes in asthmatic symptoms reported by pa-
tients [5,7,21,22]. Our study adds changes in testoster-
one levels to the known hormonal fluctuations that have
been demonstrated during the menstrual cycle. Our
study documented a significant positive correlation be-
tween PC20FEV1.0 and serum testosterone levels during
the follicular phase. In contrast, plasma levels of other
sex hormones that we measured did not correlate with
PC20FEV1.0. Moreover, we found significantly higher
testosterone levels in induced sputum of our patients
during their luteal phases when compared with testos-
terone levels measured in the follicular phases of their
menstrual cycles.
Patients presenting premenstrual asthma worsening
are frequently affected by alterations of the cyclic
changes in serum levels of progesterone [20,23]. Proges-
terone, like all other steroid hormones, is synthesized
from pregnenolone. Progesterone is the precursor of al-
dosterone, which in turn can be converted to testoster-
one [24]. It has been suggested that low testosterone
levels may significantly alter immune responses and air-
way smooth muscle reactivity [25], through genomic or
Figure 2 Relationship in each subject, measured twice (in both the follicular and luteal phases), between serum testosterone (panel A)
and FSH (panel B) on the x-axes versus the PC20meth using a logarithmic scale on the y-axes. Only the relationship between testosterone
and PC20meth reached statistical significance. P <0.05.
Figure 3 Relationship in each subject, evaluated twice (in both the follicular and luteal phases), between serum LH (panel A) and
prolactin (PRL; panel B) levels on the x-axes versus the PC20meth on the y-axes using a logarithmic scale. No one of the relationships
reached statistical significance. P> 0.05.
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male asthmatic patients with different hormones in-
cluding testosterone and demonstrated an improvement
in symptoms in ~90% of them showing an improvement
in about 90% of them [26]. Furthermore, Mileva et al.,
found low levels of testosterone in blood samples from
patients with severe and moderately severe asthma
when compared with patients with mild asthma [27]. In
our study, in addition to higher testosterone levels, we
also documented significantly higher cAMP concentra-
tions and lower PDE activity in induced sputum sam-
ples from patients in the luteal phase when compared
with PDE activity measured during the follicular phase.
PDEs are a diverse family of enzymes that play a key
role in reducing levels of the second messenger, cAMP,
and hence bronchial smooth muscle tone. Thus, the
relatively low PDE activity in sputum samples from pa-
tients during the luteal phase of the menstrual cycle
may contribute to the increased airway levels of cAMP
in these subjects in their luteal phase and vice versa for
the follicular phase. Although sputum testosterone levels
correlated indirectly with sputum PDE activity during the
various phases of the menstrual cycle, our in vitro results
exclude the possibility that testosterone directly inhibits
the catalytic activity of PDE. It is possible that an as-yet-
unidentified testosterone-induced factor inhibits PDE ac-
tivity in the airways of female asthmatics during the luteal
phases of their menstrual cycles. In previous studies, we
demonstrated that vasodilator effect of testosterone in-
volves H2S, a novel gaseous mediator [28], which, in turn,
may act as an endogenous inhibitor of PDE activity [29].
Therefore, we speculate that H2S mediates the inhibitory
effect of testosterone on PDE activity in the airways of
PMA subjects.
In rabbits, testosterone deficiency induced by castra-
tion reduced trabecular smooth muscle content, and this
reduction was restored by testosterone treatment [30].
Moreover, the ability of testosterone to regulate PDE
Figure 4 Relationship in each subject, evaluated twice (in both the follicular and luteal phases), between serum 17β-estradiol (ESTR;
panel A) and progesterone (PRG; panel B) levels on the x-axes versus the PC20meth on the y-axes using a in logarithmic scale. No one
of the relationships reached statistical significance. P>0.05.
Figure 5 cAMP levels in induced sputum samples from
asthmatic patients. Sputum cAMP levels were significantly higher
in the luteal phase when compared with the follicular phase of the
menstrual cycle. Data are mean±SEM (n=36). Follicular phase vs
luteal phase; ***indicates P<0.001.
Figure 6 Testosterone levels in induced sputum samples from
asthmatic patients. Sputum testosterone levels were significantly
higher in the luteal phase when compared with levels measured in
the follicular phase of the menstrual cycle. Data are mean±SEM
(n=36). Follicular phase vs luteal phase; ***indicates P <0.001.
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demonstrated [31]. In a human study, Aversa et al. in-
vestigated the role of androgens in regulating trabecular
smooth muscle relaxation in the corpus cavernosum in
men with erectile dysfunctioni nr e s p o n s et ov a s o a c t i v e
challenge [32]. The findings indicated that, in men with
erectile dysfunction, low testosterone levels correlate
with impaired relaxation of cavernous endothelial and
corporeal smooth muscle cells independently of age.
These findings provide some clinical evidence that andro-
gens regulate smooth muscle function in vivo. Finally,
reduced responsiveness to β2-agonists has been observed
in surgically removed bronchial tissue from asthmatic
patients [33]. In addition, testosterone promotes smooth
muscle relaxation in preparations of bronchial tissue iso-
lated from asthmatic animals with desensitized beta-
adrenoceptors [34] and potentiates isoprenaline-mediated
relaxation of bronchial smooth muscle [35]. Taken to-
gether, these studies suggest that smooth muscle tone in
different tissues (trachea, bronchi, penis and the vascula-
ture) is at least partially androgen-dependent.
The interpretation of our results should take into ac-
count the existing experimental and clinical data show-
ing that female sex hormones influence lung function,
airway responsiveness, and inflammation, but their ef-
fects vary depending on the experimental models and
the end points analyzed [36].
Conclusions
In conclusion, our data provide evidence that variations
in testosterone levels during the menstrual cycle may
contribute to fluctuations of PC20FEV1.0 during the
menstrual cycle of premenopausal women. Obviously,
this is a biologic phenomenon that might not even have
automatically clinical implication, as demonstrated by
absence of perimenstrual asthma in our population dur-
ing the study. Our results suggest that additional studies
are needed to assess whether targeting testosterone
and/or cAMP in asthmatic patients have potential to
improve the management of the worsening of asthma
during the menstrual cycle.
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Figure 7 % PDE activity in induced sputum samples from
asthmatic patients. % PDE activity was significantly higher in the
follicular phase when compared with levels measured in the luteal
phase of the menstrual cycle. Data are mean± SEM (n =36).
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kit. IBMX is a non selective PDEs inhibitor, used as positive
control. P> 0.05.
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